Tetraphase Pharmaceuticals Announces Corporate Reorganization Aimed at Maximizing XERAVA™ (Eravacycline) Commercial Opportunity
Company to Eliminate Internal Research Function and Explore Pipeline Out-licensing Opportunities to Focus the Company’s Resources on XERAVA™ Commercial Success…